VRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Vertex Pharmaceuticals Inc (VRTX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, promising product pipeline, and positive analyst sentiment. Despite minor insider and hedge fund selling, the long-term growth prospects outweigh the short-term risks.
The technical indicators suggest a moderately bullish trend. The MACD is positive at 0.594, indicating upward momentum, while the RSI is neutral at 54.018. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its pivot level of 480.689, with key resistance at 497.449 and support at 463.928.
Additionally, the potential acquisition of Crispr Therapeutics could strengthen its position in gene-editing technologies.
Insider selling has increased by 487.04% over the last month, and hedge funds are also selling, with a 149.17% increase in selling activity last quarter. These trends could indicate some short-term concerns. Additionally, the pre-market price is down 0.86%, reflecting slight negative sentiment.
Vertex reported strong Q4 2025 financials with revenue of $3.19 billion (up 9.55% YoY), net income of $1.19 billion (up 30.46% YoY), and EPS of 4.65 (up 30.99% YoY). Gross margin remained stable at 85.39%, with a minor YoY decline of 0.08%.
Analysts are overwhelmingly positive on Vertex, with multiple firms raising price targets. Notable updates include H.C. Wainwright's $591 target, Barclays' $607 target, and Cantor Fitzgerald's $590 target. Analysts highlight the company's strong cystic fibrosis franchise, promising pipeline, and potential blockbuster drugs like povetacicept and inaxaplin.
